274 related articles for article (PubMed ID: 28740920)
21. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.
Saigal K; Hurley J; Takita C; Reis IM; Zhao W; Rodgers SE; Wright JL
Clin Breast Cancer; 2013 Oct; 13(5):335-43. PubMed ID: 23850216
[TBL] [Abstract][Full Text] [Related]
22. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
Daveau C; Stevens D; Brain E; Berges O; Villette S; Moisson P; Gardner M; De la Lande B; Lasry S; Labib A; Le Scodan R
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):337-42. PubMed ID: 20171795
[TBL] [Abstract][Full Text] [Related]
23. Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy.
Kandula S; Switchenko JM; Harari S; Fasola C; Mister D; Yu DS; Zelnak AB; Torres MA
Int J Breast Cancer; 2015; 2015():147476. PubMed ID: 26266050
[TBL] [Abstract][Full Text] [Related]
24. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials.
Werutsky G; Untch M; Hanusch C; Fasching PA; Blohmer JU; Seiler S; Denkert C; Tesch H; Jackisch C; Gerber B; Schneeweiss A; Link T; Krug D; Huober J; Rhiem K; Kühn T; Vladimirova V; Nekljudova V; Loibl S
Eur J Cancer; 2020 May; 130():92-101. PubMed ID: 32179450
[TBL] [Abstract][Full Text] [Related]
25. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
[TBL] [Abstract][Full Text] [Related]
26. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.
Tendulkar RD; Rehman S; Shukla ME; Reddy CA; Moore H; Budd GT; Dietz J; Crowe JP; Macklis R
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e577-81. PubMed ID: 22560546
[TBL] [Abstract][Full Text] [Related]
27. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Hortobagyi GN; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Buchholz TA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):351-7. PubMed ID: 15890574
[TBL] [Abstract][Full Text] [Related]
28. Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.
Zhang Y; Zhang Y; Liu Z; Qin Z; Li Y; Zhao J; Ma X; Yang Q; Han N; Zeng X; Guo H; Zhang N
J Oncol; 2021; 2021():6632635. PubMed ID: 33564308
[TBL] [Abstract][Full Text] [Related]
29. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy.
Cheng JC; Chen CM; Liu MC; Tsou MH; Yang PS; Jian JJ; Cheng SH; Tsai SY; Leu SY; Huang AT
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):980-8. PubMed ID: 11958892
[TBL] [Abstract][Full Text] [Related]
30. Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis.
Perez CA; Zumsteg ZS; Gupta G; Morrow M; Arnold B; Patil SM; Traina TA; Robson ME; Wen YH; McCormick B; Powell SN; Ho AY
Breast Cancer Res Treat; 2013 Jun; 139(2):497-506. PubMed ID: 23645006
[TBL] [Abstract][Full Text] [Related]
31. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period.
Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
J Pathol Transl Med; 2017 Jan; 51(1):69-78. PubMed ID: 28013533
[TBL] [Abstract][Full Text] [Related]
33. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
[TBL] [Abstract][Full Text] [Related]
34. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
Liao Z; Strom EA; Buzdar AU; Singletary SE; Hunt K; Allen PK; McNeese MD
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1191-200. PubMed ID: 10889372
[TBL] [Abstract][Full Text] [Related]
35. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
[TBL] [Abstract][Full Text] [Related]
36. Outcome following local-regional recurrence in women with early-stage breast cancer: impact of biologic subtype.
Braunstein LZ; Niemierko A; Shenouda MN; Truong L; Sadek BT; Abi Raad R; Wong JS; Punglia RS; Taghian AG; Bellon JR
Breast J; 2015; 21(2):161-7. PubMed ID: 25559656
[TBL] [Abstract][Full Text] [Related]
37. Outcomes Following a Moderately Hypofractionated Adjuvant Radiation (START B Type) Schedule for Breast Cancer in an Unscreened Non-Caucasian Population.
Chatterjee S; Arunsingh M; Agrawal S; Dabkara D; Mahata A; Arun I; Shrimali RK; Achari R; Mallick I; Ahmed R
Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):e165-72. PubMed ID: 27369459
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy.
Stecklein SR; Park M; Liu DD; Valle Goffin JJ; Caudle AS; Mittendorf EA; Barcenas CH; Mougalian S; Woodward WA; Valero V; Sahin AA; Yang WT; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):568-577. PubMed ID: 29928946
[TBL] [Abstract][Full Text] [Related]
39. [Role of locoregional radiation therapy in breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. The Institut Curie-Hôpital René-Huguenin experience].
Le Scodan R; Bruant S; Selz J; Bollet MA; Daveau C; de la Lande B; Lerebours F; Labib A; Stevens D
Cancer Radiother; 2011 Dec; 15(8):675-82. PubMed ID: 21831686
[TBL] [Abstract][Full Text] [Related]
40. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
